Artiva Biotherapeutics, Inc.
A complete Wall Street Score is unavailable because required model components are missing. Missing model components: revenue, financial, Buffett-style model component. These are scoring components, not a claim that the company has no assets or earnings. Missing inputs are not zero and do not by themselves make this a weak company. Available financial statements and source-backed research remain visible.
ARTV · Price history
Price at last available close
$4.23
−$2.80 (-39.83%) 1M
2026-10-29
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Artiva Biotherapeutics, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma.
How they make money
Artiva Biotherapeutics is a clinical-stage biotechnology company that generates revenue primarily through license and development support agreements. The company focuses on the research, development, and commercialization of allogeneic natural killer (NK) cell therapies for autoimmune diseases and cancers.
Products & services
The company's pipeline includes AlloNK, an allogeneic NK cell therapy candidate, and other CAR-NK product candidates currently in clinical development for various autoimmune and oncology indications.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Clinical trial collaboratorsSource
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials and product candidates.Source
Business relationships & partnerships
- GC Cell — The company maintains an agreement with GC Cell, which granted Artiva an exclusive, royalty-bearing license in the Artiva Territory to research, develop, manufacture, and commercialize AB-205.Source
Strengths
- Proprietary allogeneic NK cell therapy platformSource
Sources
Company-specific research
Questions worth answering for ARTV
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can ARTV fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is ARTV likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for ARTV to reach sustainable profitability?
- •What future growth or profitability would be needed to justify ARTV's current valuation?
- •What does the current corporate distress warning mean for the reliability or interpretation of ARTV's score?
Essential Investment Snapshot
Market Cap
$206.8M
P/E Ratio
-2.2
EPS
$-3.31
52-Week High
$14.53
52-Week Low
$2.71
Beta
2.20
Analyst Target
$37.50
Shares Outstanding
48.9M
Total Debt
$9.8M
Dividend
No current dividend
Liquidation Value / Share
$7.11
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for ARTV
Detected from reported data — verify before acting.Material dilution — approximately 100.0% share-count growth
Shares outstanding increased approximately 100.0% across stored score snapshots. This is material dilution and is applying a Wall Street Score ceiling of 35.
MAJOR RED FLAG: Reverse split proposed / authorized
A recent SEC filing discusses authorization, approval, or a proposal for a reverse stock split. This is treated as a major distress/listing-risk signal and caps Wall Street Score below 30 while pending.
Supporting filingCRITICAL: Bankruptcy / liquidation risk
A recent SEC filing contains bankruptcy/liquidation language. Wall Street Score is capped at 10.
Supporting filingM&A headline · Aug 26, 2026
2,353,304 Shares in Artiva Biotherapeutics, Inc. $ARTV Acquired by 5AM Venture Management LLC — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Defense WorldCommunity Sentiment
0 active · 0 total callsNo personal call yet on ARTV.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary allogeneic NK cell therapy platform.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and expectation of future losses.
- −Dependence on third-party manufacturers for clinical supply.
- −Shares outstanding increased approximately 100.0% across stored score snapshots. This is material dilution and is applying a Wall Street Score ceiling of 35.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$4.23
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: -99.3%
Revenue changed sharply from 2023 to 2024. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $251K | $33.5M | ···· | ···· | ···· |
| Cost of Revenue | — | $2.6M | $0.00 | $0.00 | ···· | ···· | ···· |
| Gross Profit | — | -$2.6M | $251K | $33.5M | ···· | ···· | ···· |
| Research & Development | — | $69.5M | $50.3M | $50.3M | ···· | ···· | ···· |
| SG&A Expenses | — | $20.3M | $17.2M | $13.9M | ···· | ···· | ···· |
| Operating Expenses | — | $88.0M | $67.5M | $64.2M | ···· | ···· | ···· |
| EBITDA | — | -$81.3M | -$56.1M | -$25.4M | ···· | ···· | ···· |
| Operating Income | — | -$90.6M | -$67.3M | -$30.7M | ···· | ···· | ···· |
| Interest Expense | — | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· |
| Income Before Tax | — | -$83.9M | -$58.5M | -$27.6M | ···· | ···· | ···· |
| Income Tax Expense | — | $0.00 | $0.00 | $72K | ···· | ···· | ···· |
| Net Income | — | -$83.9M | -$58.5M | -$27.7M | ···· | ···· | ···· |
| Basic EPS | — | $-3.43 | $-5.20 | $-1.19 | ···· | ···· | ···· |
| Basic Shares | 39.41M | 24.44M | 24.36M | 23.28M | ···· | ···· | ···· |
| Diluted Shares | 39.41M | 24.44M | 24.36M | 23.28M | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.63
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-25.5%
Cash Change
+958.9%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included cash levels, debt levels. Pressure indicators included EPS growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS declined 27.6%. Cash increased 958.9%. Total debt declined 25.5%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
40
Smart Money
40
Number of Gurus
1
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren's Disease
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
Rumor Mill · ARTV
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial